Fundraising FoxSamsara BioCapital — 2023 Investments
5 investments dated 2023 · listed companies and verified rows first · show all
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAscenta CapitalLongitude CapitalF-Prime Capital
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)
Co-investorsVersant VenturesGilead Sciences
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureWellington ManagementAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture+1 more
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalVertex Ventures HCThird Rock Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.